Ocostec seeking to develop new RA drug

Published: 2011-11-09 06:57:00

Updated: 2011-11-09 06:57:00

Oscotec Inc., bone specialized bioengineering company, said that it presented its experimental drug candidate for the treatment of rheumatoid arthritis (RA) in 2011 Annual Scientific meeting of the American College of Rheumatology (ACR), which are being held in Chicago between November 5-9.

SKI-O-282 is part of a new class of rheumatoid arthritis drugs that blocks syk kinase, which can trigg...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.